MSB 1.85% $1.52 mesoblast limited

New Covid 19 treatment, page-181

  1. 14 Posts.
    lightbulb Created with Sketch. 38

    Wow. Seems very low considering the near term potential we have. I hope SI does not accept such an offer and instead licences out each major indication (aGVHD, COVID/ARDS, Heart, Back, GI) to a different big pharma. Some luck with the FDA and I can see the price surpassing $20 in the next few years.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.